Drug Trial Radar · NCT04777201
A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
Last checked: Nov 20, 2026Latest source record: Oct 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,036
Actual
Start
Apr 19, 2021
Primary completion
Sep 3, 2024
Study completion Sep 3, 2024
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Mar 2, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This main long-term extension study is designed to evaluate the long-term safety and tolerability of faricimab 6 milligrams (mg) administered by intravitreal injection at a personalized treatment interval (PTI) to participants with neovascular age-related macular degeneration (nAMD) who enrolled in and completed one of the Phase III studies: GR40306 (NCT03823287) or GR40844 (NCT03823300), also referred to as the parent studies. Eligible patients who consent to participate in this main study will be enrolled upon completion of the end-of-study visit in the parent study. Additionally, there is a substudy that is being conducted. The aim of this substudy is to evaluate the impact of intravitreal faricimab on the health of the corneal endothelial cells in the study eyes of patients with nAMD to fulfill a U.S. Food and Drug Administration (FDA) post-marketing requirement. The fellow eyes of the same enrolled participants in the substudy will serve as the controls.
Conditions
- Neovascular Age-related Macular Degeneration
Interventions
FaricimabDrug
Faricimab 6 mg will be administered by intravitreal (IVT) injection into the study eye according to the personalized treatment interval (PTI) dosing regimen for the duration of the study.
Sham ProcedureOther
The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. The sham procedure will be administered to participants as appropriate during the first 12 weeks of this study in order to maintain the masking of the initial faricimab PTI.
Anti-VEGF TherapyDrug
At the discretion of the principal investigator, participants were allowed to have their fellow (non-study) eye treated with the standard of care anti-VEGF therapy (if needed) according to region-specific anti-VEGF prescribing information for the recommended dose and frequency of treatment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and Severity of Ocular Adverse Events in the Study Eye, With Severity Determined According to Adverse Event Severity Grading ScaleTime frame: From the date of first administration of faricimab through 28 days after the end of study (up to 2 years)
- Incidence of Ocular Adverse Events in the Fellow EyeTime frame: From the date of first administration of faricimab through 28 days after the end of study (up to 2 years)
- Incidence and Severity of Non-Ocular Adverse Events, With Severity Determined According to Adverse Event Severity Grading ScaleTime frame: From the date of first administration of faricimab through 28 days after the end of study (up to 2 years)
- Substudy: Percent Change in Corneal Endothelial Cell Density From Baseline at 1 Year in the Study Eye as Compared With the Fellow EyeTime frame: Baseline and 1 year
Locations
251 sites in 27 countries. Site status is shown where the registry gives one.
Barnet Dulaney Perkins Eye Center
Mesa, Arizona
Arizona Retina and Vitreous Consultants
Phoenix, Arizona
Associated Retina Consultants
Phoenix, Arizona
Retina Associates Southwest PC
Tucson, Arizona
Retinal Diagnostic Center
Campbell, California
The Retina Partners
Encino, California
South Coast Retina Center
Los Angeles, California
Northern California Retina Vitreous Associates
Mountain View, California
Southern CA Desert Retina Cons
Palm Desert, California
California Eye Specialists Medical group Inc.
Pasadena, California
Retina Consultants, San Diego
Poway, California
Retina Consultants of Southern California
Redlands, California
University of California, Davis, Eye Center
Sacramento, California
Retinal Consultants Med Group
Sacramento, California
Orange County Retina Med Group
Santa Ana, California
California Retina Consultants
Santa Barbara, California
Retina Consultants of Southern
Colorado Springs, Colorado
Colorado Retina Associates, PC
Lakewood, Colorado
Retina Group of New England
Waterford, Connecticut
Rand Eye
Deerfield Beach, Florida
Retina Group of Florida
Fort Lauderdale, Florida
Florida Eye Associates
Melbourne, Florida
Retina Care Specialists
Palm Beach Gardens, Florida
Retina Specialty Institute
Pensacola, Florida
Fort Lauderdale Eye Institute
Plantation, Florida
Retina Vitreous Assoc of FL
St. Petersburg, Florida
Southern Vitreoretinal Assoc
Tallahassee, Florida
Retina Associates of Florida, LLC
Tampa, Florida
Southeast Retina Center
Augusta, Georgia
Georgia Retina PC
Marietta, Georgia
Retina Consultants of Hawaii
‘Aiea, Hawaii
Northwestern Medical Group/Northwestern University
Chicago, Illinois
University Retina and Macula Associates, PC
Oak Forest, Illinois
Prairie Retina Center
Springfield, Illinois
Raj K. Maturi, MD PC
Indianapolis, Indiana
Wolfe Eye Clinic
West Des Moines, Iowa
Retina Associates
Lenexa, Kansas
Maine Eye Center
Portland, Maine
Retina Specialists
Baltimore, Maryland
The Retina Care Center
Baltimore, Maryland
Showing 40 of 251 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.